Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sandra Grañana Castillo"'
Autor:
Thao Pham, Mohamed Ghafoor, Sandra Grañana-Castillo, Catia Marzolini, Sara Gibbons, Saye Khoo, Justin Chiong, Dennis Wang, Marco Siccardi
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-13 (2024)
Abstract Drug-drug interaction (DDI) may result in clinical toxicity or treatment failure of antiretroviral therapy (ARV) or comedications. Despite the high number of possible drug combinations, only a limited number of clinical DDI studies are condu
Externí odkaz:
https://doaj.org/article/8878a887e0bd40a8bef147c3ab9e97c1
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Tuberculosis remains the leading cause of death among people living with HIV. Rifapentine is increasingly used to treat active disease or prevent reactivation, in both cases given either as weekly or daily therapy. However, rifapentine is an inducer
Externí odkaz:
https://doaj.org/article/daaf3f7d3f2b42628b11fd58a9e08d20
Autor:
Maiara Camotti Montanha, Nicolas Cottura, Michael Booth, Daryl Hodge, Fazila Bunglawala, Hannah Kinvig, Sandra Grañana-Castillo, Andrew Lloyd, Saye Khoo, Marco Siccardi
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created
Externí odkaz:
https://doaj.org/article/32eb66361be14f55b60c46c7d5117e7c
Autor:
Sandra Grañana-Castillo, Angharad Williams, Thao Pham, Saye Khoo, Daryl Hodge, Asangaedem Akpan, Rachel Bearon, Marco Siccardi
Publikováno v:
Clinical Pharmacokinetics. 62:737-748
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f867485c0d4cc29577e88e6e354b2fc
https://doi.org/10.1007/s40262-023-01229-3
https://doi.org/10.1007/s40262-023-01229-3
Autor:
Daryl Hodge, Eva Maria Hodel, Elen Hughes, Phoebe Hazenberg, Sandra Grañana Castillo, Sara Gibbons, Duolao Wang, Fiona Marra, Catia Marzolini, David Back, Saye Khoo
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 92:97-105
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9df22b47092723a3442fe740076f09cf
https://doi.org/10.1097/qai.0000000000003122
https://doi.org/10.1097/qai.0000000000003122
Publikováno v:
The Journal of Clinical Pharmacology. 62:835-846
Despite the advancement of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV), drug-drug interactions (DDIs) remain a relevant clinical issue for people living with HIV receiving ART. Antiretroviral (ARV) drugs can b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f70f3ffe98edf1e6aff3c68ae1a88e6
https://doi.org/10.1002/jcph.2025
https://doi.org/10.1002/jcph.2025
Autor:
Fazila Bunglawala, Daryl Hodge, Sandra Grañana-Castillo, Saye Khoo, Michael Booth, Andrew Lloyd, Marco Siccardi, Nicolas Cottura, Maiara Camotti Montanha, Hannah Kinvig
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a25f0daa354199e655d8e1e8f63a47a9
https://www.frontiersin.org/articles/10.3389/fphar.2022.814134/full
https://www.frontiersin.org/articles/10.3389/fphar.2022.814134/full